Clearstone Central Laboratories, the Canada-based provider of central lab services for late-stage clinical trials, has entered into a preferred provider relationship with Mitsubishi Chemical Medience Corporation, the market-leader for clinical and diagnostic laboratory testing services in Japan.

The partnership will give both companies’ clients “seamless” access to College of American Pathologists (CAP)-accredited laboratories for safety and specialty testing services throughout the Asia-Pacific region and worldwide, they say.

That includes not only Clearstone’s laboratory in China but its global laboratory network, while Clearstone customers will be able to tap into Mitsubishi’s laboratory network in Japan.

According to Clearstone’s chief executive officer (CEO), Lewis Cameron, the relationship between the Canadian company and Mitsubishi Chemical Medience Corporation has been developing over the last year.

“Mitsubishi is a well-established leader in Japan, and this agreement extends their reach and capabilities to other strategic markets, including our renowned laboratory in China,” Cameron stated.

“We look forward to aligning our operational and business development activities, as well as providing our clients with seamless access to the Japanese market.”

Pharmaceutical sponsors the world over continue to look to new and emerging markets for drug development opportunities, “and our clients are no different”, said Dr Toshihiko Yoshitomi, CEO of Mitsubishi Chemical Medience.

“We are excited to be working closely with the market leader in China, and are confident our partnership with Clearstone will provide new channels of growth and competitive advantage for both companies,” he added.

Last August, Clearstone announced a global collaboration with the Esoterix Clinical Trials Services division of Laboratory Corporation of America Holdings (LabCorp).

It opened up a network of CAP-accredited central laboratories in Belgium, Canada, China, France, Singapore and the US, while creating “the largest combined [biomarker] assay portfolio in the industry”.